DENDREON PHARMACEUTICALS, LLC for DENDREON PHARMACEUTICALS, LLC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Sep 21, 2020 | $58,750 | Replaced |
| 3rd Quarter - Amendment | Sep 21, 2020 | $58,750 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, and H.R. 3, the Lower Drug Costs Now Act of 2019.
Foreign entity interest: Dendreon, a subsidiary of Nanjing Xinjiekou Department Store, Co. Ltd. in China.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW SAELENS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.